Get the Stockscreener App
7.20
4.00%
-0.30
Arvinas Inc stock is traded at $7.20, with a volume of 2.03M.
It is down -4.00% in the last 24 hours and down -23.16% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$7.50
Open:
$7.5
24h Volume:
2.03M
Relative Volume:
0.70
Market Cap:
$525.53M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-1.5418
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
+10.60%
1M Performance:
-23.16%
6M Performance:
-73.05%
1Y Performance:
-77.67%
1-Day Range:
$6.95
$7.50
1-Week Range:
$6.48
$7.60
52-Week Range:
$5.90
$34.11
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.20 | 475.17M | 161.10M | -308.60M | -259.90M | -4.67 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PR Newswire
Pfizer-Arvinas breast cancer drug tops AstraZeneca’s in delaying progression - WTVB
Arvinas (NASDAQ:ARVN) Shares Down 4.7%What's Next? - MarketBeat
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression - Reuters
Pfizer and Arvinas Plan FDA Submission for Breast Cancer Drug - GuruFocus
Pfizer, Arvinas report positive breast cancer drug trial - breakingthenews.net
Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2 - Seeking Alpha
(ARVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Voloridge Investment Management LLC Makes New Investment in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas And Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival For Patients With Esr1-Mutant, Er+/Her2- Advanced Breast Cancer - marketscreener.com
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progre - GuruFocus
Is Trump Media Stock a Buy After $2.5 Billion Bitcoin Treasury Deal? - The Globe and Mail
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect? - MSN
Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer - BioPharma Dive
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - GlobeNewswire
#ASCO25: Arvinas, Pfizer’s PROTAC in breast cancer no better than oral SERDs - Endpoints News
Here Are My Top 3 High-Yield Pipeline Stocks to Buy Now - The Globe and Mail
3 Dividend Stocks to Buy With $500 and Hold Forever - The Globe and Mail
Arvinas (NASDAQ:ARVN) Trading Up 7.9%Still a Buy? - MarketBeat
Arvinas to Present at Jefferies Global Healthcare Conference - GlobeNewswire
Arvinas to Present at Jefferies Global Healthcare Conference | ARVN Stock News - GuruFocus
Protein Degradation Pioneer Arvinas Reveals Latest Progress at Major Jefferies Healthcare Conference - Stock Titan
Arvinas, Inc. (NASDAQ:ARVN) Shares Purchased by Two Sigma Advisers LP - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm - Yahoo Finance
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN) - Business Wire
Prediction: 2 AI Stocks Will Be Worth More Than Apple Stock Before the End of 2026 - The Globe and Mail
3 Top High-Yield Dividend Stocks to Buy and Hold Through at Least the End of the Decade - The Globe and Mail
USDJPY Faces An Intraday Corrective Recovery: Elliott Wave Intraday Analysis - The Globe and Mail
Arvinas’s SWOT analysis: stock outlook shifts amid clinical setbacks By Investing.com - Investing.com South Africa
Woodline Partners LP Boosts Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas’s SWOT analysis: stock outlook shifts amid clinical setbacks - Investing.com
Twinbeech Capital LP Acquires New Stake in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Northern Trust Corp Buys 42,638 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Bragar Eagel & Squire, P.C. Is Investigating Organon, - GlobeNewswire
BNP Paribas Financial Markets Purchases 7,243 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and Encourages Investors to Contact the Firm - TradingView
RTW Investments LP Raises Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
(ARVN) Proactive Strategies - news.stocktradersdaily.com
Patient Square Capital LP Acquires New Shares in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Northern Trust Corp Purchases 42,638 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
UBS Group Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - Defense World
Arvinas (ARVN) Price Target Slashed by UBS but Rating Maintained | ARVN Stock News - GuruFocus
UBS Adjusts Price Target on Arvinas to $21 From $74, Maintains Buy Rating - marketscreener.com
Arvinas (ARVN) Faces Price Target Reduction Amid Trial Changes | - GuruFocus
Arvinas (ARVN) Faces Price Target Reduction Amid Trial Changes | ARVN Stock News - GuruFocus
Dimensional Fund Advisors LP Acquires 186,254 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Cantor Fitzgerald Lifts Earnings Estimates for Arvinas - MarketBeat
ATTENTION ARVN SHAREHOLDERS: Investors Who Lost Money on Arvinas, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, ... - Bluefield Daily Telegraph
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):